Skip to main content
SpringerLink
Log in

Nicotine psychopharmacology research: advancing science, public health, and global policy

  • Editorial
  • Published:
Psychopharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  • Balfour DJ, Fagerstrom KO (1996) Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 72:51–81

    Article  PubMed  CAS  Google Scholar 

  • Balfour D, Scerri C, Stewart C, Breen K et al (2006) The effects of chronic nicotine on spatial learning and cell proliferation in the dendate gyrus of the rat. Psychopharmacology - present special issue

  • Barry H III (2006) Commentary. Psychopharmacology (in press)

  • Belluzzi JD, Wang R, Leslie FM (2005) Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology 30:705–712

    Article  PubMed  CAS  Google Scholar 

  • Corrigall WA (1999) Nicotine self-administration in animals as a dependence model. Nicotine Tob Res 1:11–20

    Article  PubMed  CAS  Google Scholar 

  • Corrigall WP, Coen KM (1989) Nicotine maintains robust self-administration in rats on a limited access schedule. Psychopharmacology 99:473–478

    Article  PubMed  CAS  Google Scholar 

  • De Noble VJ, Mele PC (2006) Psychopharmacology (in press)

  • Food and Drug Administration (1995) Regulations restricting the sale and distribution of cigarettes and smokeless tobacco products to protect children and adolescents; proposed rule analysis regarding FDA's jurisdiction over nicotine-containing cigarettes and smokeless tobacco products; notice. Fed Regist 60:41314–41792

    Google Scholar 

  • Food and Drug Administration (1996) Regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents; final rule. Fed Regist 61:44396–45318

    Google Scholar 

  • Garrett B, Dwoskin L, Bardo M, Henningfield JE (2004) Behavioral pharmacology of nicotine reinforcement. In: Boyle P, Gray N, Henningfield J, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp 149–165

    Google Scholar 

  • Goldberg SR, Spealman RD, Goldberg DM (1981) Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 214:573–575

    Article  PubMed  CAS  Google Scholar 

  • Henningfield JE, Stolerman I (2005) Co-chairs and introduction to plenary symposium: nicotine psychopharmacology and policy—a look behind and a look ahead. American Psychological Association, National Meeting, Washington, DC, 18 August 2005

  • Hurt RD, Robertson CR (1998) Prying open the door to the tobacco industry's secrets about nicotine: the Minnesota Tobacco Trial. JAMA 280(13):1173–1181

    Article  PubMed  CAS  Google Scholar 

  • Kessler D (2001) A question of intent: a great American battle with a deadly industry. Public Affairs, New York

    Google Scholar 

  • Kessler D, Henningfield JE (1995) Statement of David Kessler, Commissioner of Food and Drugs, Food and Drug Administration, accompanied by Jack E. Henningfield, Chief, Clinical Pharmacology Branch, National Institute on Drug Abuse. Hearings before the subcommittee on health and the environment of the committee on energy and commerce, House of Representatives, One Hundred Third Congress, Second Session. U.S. Government Printing Office, Washington, DC, pp 36–37

  • Langley JN (1905) On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. J Physiol (Lond) 33:374–413

    Google Scholar 

  • Levin E (2006) Nicotinic effects on cognitive behavioral (in press)

  • Lewin L (1998) Phantastica: a classic survey on the use and abuse of mind-altering plants. Park Street, Rochester, VT

    Google Scholar 

  • Schwartz J (1994a) Philip Morris accused of stifling study. Washington Post, p A.01, 1 April, 1994

  • Schwartz J (1994b) Scientists testify tobacco company suppressed addiction studies. Washington Post, p A.36, 29 April 1994

  • Slade J, Bero LA, Hanauer P, Barnes DE, Glantz SA (1995) Nicotine and addiction. The Brown and Williamson documents. JAMA 274:225–233

    Article  PubMed  CAS  Google Scholar 

  • Vagg R, Chapman S (2005) Nicotine analogues: a review of tobacco industry research interests. Addiction 100:701–712

    Article  PubMed  Google Scholar 

  • Wayne GF, Connolly GN, Henningfield JE (2004) Assessing internal tobacco industry knowledge of the neurobiology of tobacco dependence. Nicotine Tob Res 6:927–940

    Article  PubMed  Google Scholar 

  • World Bank (1999) Curbing the epidemic: governments and the economics of tobacco control. World Health Organization, Washington, DC

    Google Scholar 

  • World Health Organization (2001) Advancing knowledge on regulating tobacco products. World Health Organization, Geneva, Switzerland

    Google Scholar 

  • World Health Organization (2004) Recommendation: guiding principles for the development of tobacco product research and testing capacity and proposed protocols for the initiation of tobacco product testing. Geneva, Switzerland: World Health Organization, Study Group on Tobacco Product Regulation (TobReg). Retrieved from http://www.who.int/tobacco/global_interaction/tobreg/goa_2003_principles/en/

  • World Health Organization (2005) WHO framework convention on tobacco control. WHO Document Production Services, Geneva, Switzerland

    Google Scholar 

  • Zacny JP (2005) From the president's desk. Psychopharmacology and substance abuse news 38(1):1–3 http://www.apa.org/divisions/div28/newsletter/archive/News_2005_38_1.pdf

Download references

Acknowledgement

Jack Henningfield was supported by The Robert Wood Johnson Foundation Innovators Awards Program in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine and Pinney Associates. He provides consulting services on tobacco dependence treatment products, has a financial interest in tobacco dependence treatment medicine, and has testified against the tobacco industry on behalf of the US Department of Justice and other plaintiffs.

Author information

Authors and Affiliations

  1. Pinney Associates, Bethesda, MD, USA

    Jack E. Henningfield

  2. Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Jack E. Henningfield

  3. Institute of Psychiatry King’s College London, London, UK

    Ian P. Stolerman

  4. Psychology, Psychiatry, Pharmacology and Neuroscience, Tufts University, Medford and Boston, MA, USA

    Klaus A. Miczek

Authors
  1. Jack E. Henningfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian P. Stolerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Klaus A. Miczek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jack E. Henningfield.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Henningfield, J.E., Stolerman, I.P. & Miczek, K.A. Nicotine psychopharmacology research: advancing science, public health, and global policy. Psychopharmacology 184, 263–265 (2006). https://doi.org/10.1007/s00213-005-0297-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-005-0297-8

Search

Navigation